English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

We compared changes in blood glucose ( BG ) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes ( T1D ) treated with insulin degludec ( IDeg ) or insulin glargine ( IGlar ) in a randomized, open‐label, two‐period, crossover trial. After individual titration and a steady‐state period, patients performed 30 min of moderate‐intensity cycle ergometer exercise (65% peak rate of oxygen uptake).  BG , counter‐regulatory hormones and hypoglycaemic episodes were measured frequently during and for 24 h after exercise.  BG  changes during exercise were similar with  IDeg  and  IGlar  [estimated treatment difference ( ETD ) for maximum  BG  decrease: 0.14 mmol/l; 95% confidence interval ( CI ) −0.15, 0.42; p = 0.34], as was mean  BG  ( ETD  −0.16 mmol/l; 95%  CI  −0.36, 0.05; p = 0.13). No hypoglycaemic episodes occurred during exercise. Post‐exercise mean  BG , counter‐regulatory hormone response and number of hypoglycaemic episodes in 24 h after starting exercise were similar with  IDeg  (18 events in 13 patients) and  IGlar  (23 events in 15 patients). This clinical trial showed that, in patients with  T1D  treated with a basal‐bolus regimen, the risk of hypoglycaemia induced by moderate‐intensity exercise was low with  IDeg  and similar to that with  IGlar .

diabetes, obesity and metabolism

Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial